cancer risk in type 2 diabetes mellitus metabolic links and therapeutic considerations癌症的风险在2型糖尿病代谢链接和治疗方面的考虑.pdfVIP

Hindawi Publishing Corporation Journal of Nutrition and Metabolism Volume 2011, Article ID 708183, 11 pages doi:10.1155/2011/708183 Review Article Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations Grace Sun and Sangeeta R. Kashyap Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic, Cleveland, OH 44195, USA Correspondence should be addressed to Sangeeta R. Kashyap, kashyas@ Received 23 November 2010; Revised 10 February 2011; Accepted 24 March 2011 Academic Editor: Maria Luz Fernandez Copyright © 2011 G. Sun and S. R. Kashyap. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Type 2 diabetes mellitus (DM2) is increasing in incidence, creating worldwide public health concerns and impacting morbidity and mortality rates. An increasing number of studies have demonstrated shared associations between DM2 and malignancy, including key clinical, biochemical, and metabolic commonalities. This paper will attempt to explore the relationship between the various types of cancer and diabetes, the common metabolic pathways underlying cancer development, and the potential impact of various antidiabetes therapies on cancer risk. 1. Introduction and the metabolic syndrome, has also been linked to breast, colorectal, liver, and endometrial, malignancies [5]. Dietary The association between diabetes and cancer was described choices high in glycemic load and saturated fat and low in long before the 21st century, as far back as 1885 [ 1]. DM2